Mangoceuticals, INC 10-Q quarterly reports

Mangoceuticals, Inc. reported continued net losses and a significant accumulated deficit in its Q2 2026 filing, while also detailing a pending business combination with Nuclea Energy Inc. and management changes.

Mangoceuticals, Inc. reported a net loss of $3.4 million for the first quarter of 2026, with revenues declining compared to the prior year period.

Mangoceuticals, Inc. reported a significantly increased net loss for the third quarter and first nine months of 2025, driven by higher operating expenses and a drop in revenue, despite an improved cash position from financing activities.

Mangoceuticals, Inc. filed an amended quarterly report for Q2 2025, revealing increased net losses and significant stock-based compensation, alongside strategic intellectual property acquisitions and ongoing financing efforts.

Mangoceuticals, Inc. reported a significant increase in net loss and a decrease in revenue for the first six months of 2025, raising substantial doubt about its ability to continue as a going concern.

Mangoceuticals' Q1 2025 revenue decreased due to platform transition issues, while the company continues to pursue strategic alternatives and secure additional funding.

Mangoceuticals, Inc. reports a net loss of $1.99 million for the third quarter of 2024, with a decrease in revenue due to platform migration issues.

Mangoceuticals, Inc. released its second quarter 2024 financial results, detailing revenue growth, increased operating expenses, and strategic moves including a patent acquisition and new distribution agreement.

Mangoceuticals, Inc. reports a 113% increase in revenue for the first quarter of 2024 compared to the same period last year, alongside a reduced net loss.